| # | Title | Journal | Year | Citations |
|---|
|
| 1 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | Autophagy | 2016 | 4,789 |
| 2 | Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked | Science | 1997 | 4,676 |
| 3 | In vivo cancer targeting and imaging with semiconductor quantum dots | Nature Biotechnology | 2004 | 4,504 |
| 4 | Cancer treatment and survivorship statistics, 2016 | Ca-A Cancer Journal for Clinicians | 2016 | 4,237 |
| 5 | The Somatic Genomic Landscape of Glioblastoma | Cell | 2013 | 4,133 |
| 6 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | Lancet Oncology, The | 2014 | 3,566 |
| 7 | Cancer treatment and survivorship statistics, 2019 | Ca-A Cancer Journal for Clinicians | 2019 | 3,484 |
| 8 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 3,158 |
| 9 | Therapeutic Nanoparticles for Drug Delivery in Cancer | Clinical Cancer Research | 2008 | 2,610 |
| 10 | Lung cancer: current therapies and new targeted treatments | Lancet, The | 2017 | 2,436 |
| 11 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma | Lancet Oncology, The | 2016 | 2,003 |
| 12 | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | New England Journal of Medicine | 2020 | 1,901 |
| 13 | Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia | Blood | 2019 | 1,325 |
| 14 | Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma | New England Journal of Medicine | 2016 | 1,290 |
| 15 | Cancer treatment and survivorship statistics, 2022 | Ca-A Cancer Journal for Clinicians | 2022 | 1,258 |
| 16 | Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia | JAMA - Journal of the American Medical Association | 2015 | 1,242 |
| 17 | Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410 | Journal of the National Cancer Institute | 2011 | 1,073 |
| 18 | Breast cancer statistics, 2015: Convergence of incidence rates between black and white women | Ca-A Cancer Journal for Clinicians | 2016 | 1,040 |
| 19 | Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis | BMC Cell Biology | 2013 | 957 |
| 20 | Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial | Lancet, The | 2019 | 937 |
| 21 | Breast Cancer Statistics, 2022 | Ca-A Cancer Journal for Clinicians | 2022 | 912 |
| 22 | Engineering strategies to overcome the current roadblocks in CAR T cell therapy | Nature Reviews Clinical Oncology | 2020 | 901 |
| 23 | Intertumoral Heterogeneity within Medulloblastoma Subgroups | Cancer Cell | 2017 | 886 |
| 24 | A Novel Five-Transmembrane Hematopoietic Stem Cell Antigen: Isolation, Characterization, and Molecular Cloning | Blood | 1997 | 877 |
| 25 | Mammalian Krüppel-Like Factors in Health and Diseases | Physiological Reviews | 2010 | 855 |
| 26 | 2016 US lymphoid malignancy statistics by World Health Organization subtypes | Ca-A Cancer Journal for Clinicians | 2016 | 846 |
| 27 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma | Leukemia | 2008 | 799 |
| 28 | The BATTLE Trial: Personalizing Therapy for Lung Cancer | Cancer Discovery | 2011 | 796 |
| 29 | Subgroup-specific structural variation across 1,000 medulloblastoma genomes | Nature | 2012 | 784 |
| 30 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis | Lancet Oncology, The | 2016 | 748 |
| 31 | Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial | Lancet, The | 2016 | 746 |
| 32 | Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial | Lancet Oncology, The | 2014 | 707 |
| 33 | International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Leukemia | 2009 | 702 |
| 34 | Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002 | Journal of Clinical Oncology | 2007 | 666 |
| 35 | Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients | Proceedings of the National Academy of Sciences of the United States of America | 2017 | 663 |
| 36 | Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193) | Journal of Clinical Oncology | 2003 | 658 |
| 37 | Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial | Lancet Oncology, The | 2013 | 638 |
| 38 | American Cancer Society lung cancer screening guidelines | Ca-A Cancer Journal for Clinicians | 2013 | 619 |
| 39 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report | Blood | 2015 | 609 |
| 40 | Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions | PLoS ONE | 2013 | 606 |
| 41 | Human MSC Suppression Correlates With Cytokine Induction of Indoleamine 2,3-Dioxygenase and Bystander M2 Macrophage Differentiation | Molecular Therapy | 2012 | 601 |
| 42 | Preventing and Managing Toxicities of High-Dose Methotrexate | Oncologist | 2016 | 585 |
| 43 | Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study | Lancet Oncology, The | 2018 | 576 |
| 44 | Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group | Journal of Clinical Oncology | 2003 | 571 |
| 45 | Application of Nanotechnology in Cancer Therapy and Imaging | Ca-A Cancer Journal for Clinicians | 2008 | 563 |
| 46 | An intra-tumoral niche maintains and differentiates stem-like CD8 T cells | Nature | 2019 | 563 |
| 47 | Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis | Neuro-Oncology | 2005 | 562 |
| 48 | CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences | Nucleic Acids Research | 2014 | 561 |
| 49 | The genetic landscape of mutations in Burkitt lymphoma | Nature Genetics | 2012 | 531 |
| 50 | Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies | Drug Resistance Updates | 2016 | 530 |
